Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 4/20 | 0.41 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL578638 | 1.00 | BTK (0.49) | BTKKDM1AMAOBCTSKGAA | |
| SCHEMBL3702152 | 0.86 | BTK (0.61) | BTKKDM1AMAOBCTSKGAA | |
| SCHEMBL1406894 | 0.86 | BTK (0.61) | BTKKDM1AMAOBCTSKGAA | |
| SCHEMBL10343938 | 0.86 | BTK (0.61) | BTKKDM1AMAOBCTSKGAA | |
| SCHEMBL3702157 | 0.86 | BTK (0.61) | BTKKDM1AMAOBCTSKGAA | |
| SCHEMBL2963241 | 0.85 | BTK (0.50) | BTKKDM1AMAOBCTSKGAA | |
| SCHEMBL19560741 | 0.85 | BTK (0.50) | BTKKDM1AMAOBCTSKGAA | |
| SCHEMBL1607763 | 0.85 | BTK (0.50) | BTKKDM1AMAOBCTSKGAA | |
| SCHEMBL1422443 | 0.85 | BTK (0.50) | BTKKDM1AMAOBCTSKGAA | |
| SCHEMBL15584722 | 0.85 | BTK (0.50) | BTKKDM1AMAOBCTSKGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11578084-B2 | Condensed ring compounds having dopamine D3 receptor antagonistic effect | SHIONOGI & CO., LTD. (JP) | 2023-02-14 | — | — | US | disclosed |
| US-20210139507-A1 | FUSED PYRIDINES WHICH ACT AS INHIBITORS OF H PGDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-05-13 | — | — | US | disclosed |
| US-20210040117-A1 | CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 RECEPTOR ANTAGONISTIC EFFECT | SHIONOGI & CO., LTD. (JP) | 2021-02-11 | — | — | US | disclosed |
| CN-111479814-A | Fused pyridines as H-PGDS inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-07-31 | — | — | CN | disclosed |
| WO-2019116256-A1 | FUSED PYRIDINES WHICH ACT AS INHIBITORS OF H-PGDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-06-20 | — | — | WO | disclosed |
| WO-2016024096-A1 | ANTIBACTERIAL COMPOUNDS | REDX PHARMA PLC (GB) | 2016-02-18 | — | — | WO | disclosed |
| US-20150297596-A1 | ISOXAZOLINES AS THERAPEUTIC AGENTS | ABBVIE INC. (US) | 2015-10-22 | — | — | US | disclosed |
| US-20150297596-A1 | ISOXAZOLINES AS THERAPEUTIC AGENTS | ABBVIE INC. (US) | 2015-10-22 | — | — | US | disclosed |
| US-9029409-B2 | Isoxazolines as therapeutic agents | ABBVIE INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029409-B2 | Isoxazolines as therapeutic agents | ABBVIE INC. (US) | 2015-05-12 | — | — | US | disclosed |
| WO-2012151158-A1 | ISOXAZOLINES AS THERAPEUTIC AGENTS | ABBOTT LABORATORIES (US) | 2012-11-08 | — | — | WO | disclosed |
| US-20120040989-A1 | 2-HYDROXYETHYL-1H-QUINOLIN-2-ONE DERIVATIVES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-02-16 | — | — | US | disclosed |
| EP-2417141-A1 | 2-HYDROXYETHYL-1H-QUINOLIN-2-ONE DERIVATIVES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY | Actelion Pharmaceuticals Ltd. (CH) | 2012-02-15 | — | — | EP | disclosed |
| US-20110288084-A1 | [4-( 1-AMINO-ETHYL) - CYCLOHEXYL ] - METHYL - AMINES AS ANTIBACTERIALS | ASTRAZENECA AB (SE) | 2011-11-24 | — | — | US | disclosed |
| EP-2370444-A1 | [4- (1-AMINO-ETHYL) -CYCLOHEXYL]-METHYL-AMINES AS ANTIBACTERIALS | AstraZeneca AB (SE) | 2011-10-05 | — | — | EP | disclosed |
| US-20110082132-A1 | [4-(1-AMINO-EHTYL) - CYCLOHEXYL] -METHYL-AMINE AND [6-(1-AMINO-EHTYL) -TETRAHYDRO-PYRAN-3-YL] -METHYL-AMINE DERIVATIVES AS ANTIBACTERIALS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-04-07 | — | — | US | disclosed |
| EP-2297107-A1 | Ý4-(1-AMINO-ETHYL) -CYCLOHEXYL¨-METHYL-AMINE AND Ý6-(1-AMINO-ETHYL) -TETRAHYDRO- PYRAN-3-YL¨-METHYL-AMINE DERIVATIVES AS ANTIBACTERIALS | Actelion Pharmaceuticals Ltd. (CH) | 2011-03-23 | — | — | EP | disclosed |
| WO-2010116337-A1 | 2-HYDROXYETHYL-1H-QUINOLIN-2-ONE DERIVATIVES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY | ACTELION PHARMACEUTICALS LTD (CH) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010055348-A1 | [4- (1-AMINO-ETHYL) -CYCLOHEXYL] -METHYL-AMINES AS ANTIBACTERIALS | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | WO | disclosed |
| WO-2009147616-A1 | [4-(1-AMINO-ETHYL) -CYCLOHEXYL] -METHYL-AMINE AND [6-(1-AMINO-ETHYL) -TETRAHYDRO- PYRAN-3-YL] -METHYL-AMINE DERIVATIVES AS ANTIBACTERIALS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040989-A1 | 2-HYDROXYETHYL-1H-QUINOLIN-2-ONE DERIVATIVES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY | NQO2, AZI2, Q6ZSR9 | BTK 2821/4885KDM1A 84/4885MAOB 1653/4885 |
| US-20110082132-A1 | [4-(1-AMINO-EHTYL) - CYCLOHEXYL] -METHYL-AMINE AND [6-(1-AMINO-EHTYL) -TETRAHYDRO-PYRAN-3-YL] -METHYL-AMINE DERIVATIVES AS ANTIBACTERIALS | DOT1L, EHMT1, Q6ZSR9 | BTK 2385/4885KDM1A 90/4885MAOB 399/4885 |
| US-20150297596-A1 | ISOXAZOLINES AS THERAPEUTIC AGENTS | CYP3A7, CYP11B2, CYP11B1 | BTK 2758/4885KDM1A 3371/4885MAOB 1423/4885 |
| US-20110288084-A1 | [4-( 1-AMINO-ETHYL) - CYCLOHEXYL ] - METHYL - AMINES AS ANTIBACTERIALS | AAAS, EEF1A1, ACMSD | BTK 2104/4885KDM1A 321/4885MAOB 52/4885 |
| US-20210139507-A1 | FUSED PYRIDINES WHICH ACT AS INHIBITORS OF H PGDS | HPGDS, HPGD, PTGS1 | BTK 3992/4885KDM1A 815/4885MAOB 843/4885 |
| US-20210040117-A1 | CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 RECEPTOR ANTAGONISTIC EFFECT | DRD3, DRD2, DRD1 | BTK 3107/4885KDM1A 3190/4885MAOB 517/4885 |
| US-11578084-B2 | Condensed ring compounds having dopamine D3 receptor antagonistic effect | DRD3, DRD2, DRD1 | BTK 3107/4885KDM1A 3190/4885MAOB 517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.